AI drug discovery firm Enveda raises $311M Series E
nathanbenaich · x · 2026-09-26
AI drug discovery company Enveda announced a $311M Series E to bring pharma into the 21st century.
Enveda's thesis: a molecule evolution has already refined is a better starting point than one designed from scratch. This year, two first-in-class molecules discovered by Enveda (ENV-294 and ENV-308) had positive human readouts, with many more behind them.
The round was led by Catalio Capital, with new investors Durable Capital Partners, ICONIQ Capital, Lightspeed, Surveyor Capital (a Citadel company), accounts advised by T. Rowe Price, Digitalis Ventures and Alderline Group, plus existing backers BaillieGifford, Premji Invest, True Ventures, Kinnevik, FPV Ventures and Dimension Capital. Investor Nathan Benaich called Enveda an "execution machine" and said he's proud to have invested from the early days.
Related event: AI drug discovery firm Enveda raises $311M at $2B valuation(2 posts)→
More from Venture
- AMAT reports Thursday: DRAM hits 26% of tool sales, outlook is the real signal — tengyanAI · 2026-11-11
- Amazon's $ANT stake and notes could equal 13-16.5% of its own market cap — RihardJarc · 2026-11-11
- Leaked guidance: $52.5B in 2026, $140B by 2027 and $280B by 2028 — zephyr_z9 · 2026-11-11
- Anthropic reportedly guiding $140B revenue for 2027 and $280B for 2028 — zephyr_z9 · 2026-11-11
- Anthropic's $26B IPO private placement: seven suppliers buying in, AMD deal tied to GPU delivery — demian_ai · 2026-11-11
- AMD's 10-Q reveals $2.9B Taalas acquisition that bakes LLM weights into hardware — deedydas · 2026-11-11